Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 15/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 13/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.79 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.79 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.79 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.79 |
| ▸ | NCOR2 | Q9Y618 | 7/20 | 0.79 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.79 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.79 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30013157 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC10HDAC6 | |
| SCHEMBL3237182 | 0.89 | HDAC1 (0.80) | HDAC1HDAC3HDAC2HDAC10HDAC6 | |
| SCHEMBL12125319 | 0.89 | HDAC1 (0.83) | HDAC1HDAC3HDAC2HDAC10HDAC6 | |
| SCHEMBL29921577 | 0.88 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC10HDAC6 | |
| SCHEMBL675185 | 0.88 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC10HDAC6 | |
| SCHEMBL1063954 | 0.88 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC10HDAC6 | |
| SCHEMBL30029834 | 0.88 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC10HDAC6 | |
| SCHEMBL16011053 | 0.87 | HDAC4 (1.00) | HDAC1HDAC3HDAC2HDAC10HDAC6 | |
| SCHEMBL1902019 | 0.87 | HDAC1 (0.97) | HDAC1HDAC3HDAC2HDAC10HDAC6 | |
| SCHEMBL8241153 | 0.87 | HDAC3 (1.00) | HDAC1HDAC3HDAC2HDAC10HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-4720316-A2 | NON-VIRAL CELL ENGINEERING | Arsenal Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20250115871-A1 | METHODS TO IMPROVE ENDURING HEMATOPOIETIC STEM CELL TRANSPLANTATION | TRAILHEAD BIOSYSTEMS INC. | 2025-04-10 | — | — | US | claimed |
| WO-2024259376-A2 | NON-VIRAL CELL ENGINEERING | ARSENAL BIOSCIENCES, INC. (US) | 2024-12-19 | — | — | WO | claimed |
| WO-2024256607-A1 | STANDARDISING PLURIPOTENT STEM CELLS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-12-19 | — | — | WO | claimed |
| US-20240398814-A1 | KRAS INHIBITOR AND HDAC INHIBITOR COMBINATION FOR THE TREATMENT OF CANCER | NORTHWESTERN UNIVERSITY | 2024-12-05 | — | — | US | claimed |
| US-20240374569-A1 | HDAC3 INHIBITORS FOR THE TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS AND LANGERHANS CELL SARCOMA | HENRY FORD HEALTH SYSTEM | 2024-11-14 | — | — | US | claimed |
| EP-4441205-A1 | METHODS AND COMPOSITIONS FOR MAINTAINING AND EXPANDING HEMATOPOIETIC STEM CELLS | Trailhead Biosystems Inc. (US) | 2024-10-09 | — | — | EP | claimed |
| CN-118302519-A | Methods and compositions for maintaining and expanding hematopoietic stem cells | 特雷尔赫德生物系统股份有限公司 | 2024-07-05 | — | — | CN | claimed |
| US-20230193205-A1 | GENE MODIFIED FIBROBLASTS FOR THERAPEUTIC APPLICATIONS | FIGENE, LLC | 2023-06-22 | — | — | US | claimed |
| WO-2023101943-A1 | METHODS AND COMPOSITIONS FOR MAINTAINING AND EXPANDING HEMATOPOIETIC STEM CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2023-06-08 | — | — | WO | claimed |
| WO-2023049798-A1 | HDAC3 INHIBITORS FOR THE TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS AND LANGERHANS CELL SARCOMA | HENRY FORD HEALTH SYSTEM (US) | 2023-03-30 | — | — | WO | claimed |
| WO-2010028193-A1 | COMPOUNDS INCLUDING PIMELIC ACID DERIVATIVES AS HDAC INHIBITORS | REPLIGEN CORPORATION (US) | 2010-03-11 | — | — | WO | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | disclosed |
| EP-4719447-A2 | METHOD TO GENERATE INDUCED RETINAL PROGENITOR CELLS AND TREATMENT USING SUCH CELLS | Academia Sinica (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-20070219244-A1 | Histone deacetylase inhibitors as therapeutics for neurological diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007058927-A1 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058927-A1 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398814-A1 | KRAS INHIBITOR AND HDAC INHIBITOR COMBINATION FOR THE TREATMENT OF CANCER | KRAS, HRAS, HDAC1 | HDAC1 3/4885HDAC3 9/4885HDAC2 13/4885 |
| US-20070219244-A1 | Histone deacetylase inhibitors as therapeutics for neurological diseases | HDAC5, HDAC1, HDAC6 | HDAC1 2/4885HDAC3 9/4885HDAC2 4/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | HDAC1 71/4885HDAC3 97/4885HDAC2 432/4885 |
| US-20240374569-A1 | HDAC3 INHIBITORS FOR THE TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS AND LANGERHANS CELL SARCOMA | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC3 1/4885HDAC2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.